Aldeyra Therapeutics, Inc. (ALDX): Price and Financial Metrics

Aldeyra Therapeutics, Inc. (ALDX): $9.03

-0.03 (-0.33%)

POWR Rating

Component Grades













Add ALDX to Watchlist
Sign Up

Industry: Biotech



in industry

ALDX Stock Price Chart Interactive Chart >

Price chart for ALDX

ALDX Price/Volume Stats

Current price $9.03 52-week high $9.20
Prev. close $9.06 52-week low $2.36
Day low $8.65 Volume 1,508,200
Day high $9.12 Avg. volume 490,537
50-day MA $6.88 Dividend yield N/A
200-day MA $5.96 Market Cap 528.94M

Aldeyra Therapeutics, Inc. (ALDX) Company Bio

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.

ALDX Latest News Stream

Event/Time News Detail
Loading, please wait...

ALDX Latest Social Stream

Loading social stream, please wait...

View Full ALDX Social Stream

Latest ALDX News From Around the Web

Below are the latest news stories about ALDEYRA THERAPEUTICS INC that investors may wish to consider to help them evaluate ALDX as an investment opportunity.

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa

LEXINGTON, Mass., March 16, 2023--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the completion of enrollment in the Phase 2 clinical trial of ADX‑2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of retinitis pigmentosa, a group of rare genetic eye diseases characterized by retinal cell death and loss of vision, for which there is no U.S. Food and Drug Administration (FDA)-approved treatment.

Yahoo | March 16, 2023

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2022 Earnings Call Transcript

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After speakers’ presentations, there will be a question-and-answer session. I would […]

Yahoo | March 11, 2023

Q4 2022 Aldeyra Therapeutics Inc Earnings Call

Q4 2022 Aldeyra Therapeutics Inc Earnings Call

Yahoo | March 10, 2023

Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

LEXINGTON, Mass., March 09, 2023--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the year ended December 31, 2022.

Yahoo | March 9, 2023

FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma

LEXINGTON, Mass., March 02, 2023--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review the New Drug Application (NDA) for ADX-2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of June 21, 2023. The FDA noted that no potential filing review issues have been identified.

Yahoo | March 2, 2023

Read More 'ALDX' Stories Here

ALDX Price Returns

1-mo 22.86%
3-mo 36.82%
6-mo 69.74%
1-year 86.19%
3-year 356.06%
5-year 8.14%
YTD 29.74%
2022 74.00%
2021 -41.69%
2020 18.07%
2019 -30.00%
2018 22.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6908 seconds.